AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin (ER)
Drug: Persantin
Drug: Acetyl salicylic acid (ASA)

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02273505

Effect of Different Food Compositions on Bioavailability of BIIL 284 BS in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS
Other: low fat meal
Other: high fat meal

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02273427

Pharmacokinetics and Safety of Asasantin Extended Release (RAD-SP) Capsules in Japanese Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Asasantin®

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02273479

Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 11054 CL
Drug: Placebo

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 96

Registration Number: NCT02273401

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin ER, new formulation
Drug: Asasantin ER, present commercial formulation

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02273531

Pharmacokinetics of Oral Desipramine With and Without Concomitant Administration of Crobenetine Infusion in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Desipramine tablet
Drug: Crobenetine infusion
Drug: Placebo infusion

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02273466

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Asasantin ER - commercial formulation
Drug: Asasantin ER (new formulation - low)
Drug: Asasantin ER (new formulation - high)
Drug: Asasantin ER (new formulation - medium)

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02273544

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin ER, new formulation II
Drug: Asasantin ER, new formulation I
Drug: Asasantin ER, present commercial formulation

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02273518

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: BI 695502
Drug: Avastin

First Posted Date: 2014-10-23

Last Posted Date: 2020-01-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 671

Registration Number: NCT02272413

Locations: 🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸
Southern California Oncology Research Alliance, Los Angeles, California, United States
🇺🇦
CI Zapor Reg Cl Oncological Dispensary of ZRC, Zhaporizhzhia, Zhaporizhzhia, Ukraine

and more 186 locations

Pharmacokinetics of Midazolam, With and Without Concomitant Administration of Crobenetine in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam, tablet
Drug: Crobenetine, i.v. infusion
Drug: Placebo

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02269202

Home Terms & Conditions Privacy Policy